Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Hilf N, et al. Among authors: bunse l. Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Nature. 2019. PMID: 30568303 Clinical Trial.
A vaccine targeting mutant IDH1 induces antitumour immunity.
Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, von Deimling A, Wick W, Platten M. Schumacher T, et al. Among authors: bunse l. Nature. 2014 Aug 21;512(7514):324-7. doi: 10.1038/nature13387. Epub 2014 Jun 25. Nature. 2014. PMID: 25043048
Proximity ligation assay evaluates IDH1R132H presentation in gliomas.
Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M. Bunse L, et al. J Clin Invest. 2015 Feb;125(2):593-606. doi: 10.1172/JCI77780. Epub 2015 Jan 2. J Clin Invest. 2015. PMID: 25555220 Free PMC article. Clinical Trial.
Mutant IDH1: An immunotherapeutic target in tumors.
Schumacher T, Bunse L, Wick W, Platten M. Schumacher T, et al. Among authors: bunse l. Oncoimmunology. 2015 Jan 7;3(12):e974392. doi: 10.4161/2162402X.2014.974392. eCollection 2014 Dec. Oncoimmunology. 2015. PMID: 25964867 Free PMC article.
Concepts in glioma immunotherapy.
Platten M, Bunse L, Wick W, Bunse T. Platten M, et al. Among authors: bunse l, bunse t. Cancer Immunol Immunother. 2016 Oct;65(10):1269-75. doi: 10.1007/s00262-016-1874-x. Epub 2016 Jul 26. Cancer Immunol Immunother. 2016. PMID: 27460064 Free PMC article. Review.
K27M-mutant histone-3 as a novel target for glioma immunotherapy.
Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M. Ochs K, et al. Among authors: bunse l, bunse t. Oncoimmunology. 2017 May 12;6(7):e1328340. doi: 10.1080/2162402X.2017.1328340. eCollection 2017. Oncoimmunology. 2017. PMID: 28811969 Free PMC article.
The promises of immunotherapy in gliomas.
Mildenberger I, Bunse L, Ochs K, Platten M. Mildenberger I, et al. Among authors: bunse l. Curr Opin Neurol. 2017 Dec;30(6):650-658. doi: 10.1097/WCO.0000000000000491. Curr Opin Neurol. 2017. PMID: 28984704 Review.
Vaccine Strategies in Gliomas.
Platten M, Bunse L, Riehl D, Bunse T, Ochs K, Wick W. Platten M, et al. Among authors: bunse l, bunse t. Curr Treat Options Neurol. 2018 Mar 28;20(5):11. doi: 10.1007/s11940-018-0498-1. Curr Treat Options Neurol. 2018. PMID: 29594595 Review.
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M. Bunse L, et al. Among authors: bunse t. Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9. Nat Med. 2018. PMID: 29988124
50 results